Aequus and Scientus Agree to Terms for a Medical Cannabis …

VANCOUVER, BC–(Marketwired – August 01, 2017) – Aequus Pharmaceuticals Inc., (“Aequus”) (TSX VENTURE: AQS)(OTCQB: AQSZF), a specialty life sciences company focused on providing patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc., (“Scientus”), a biopharmaceutical company focused on RD and product commercialization for extracts and formulations related to medical cannabinoids and their derivatives, announced today that they have signed a non-binding term sheet on a collaboration to develop, assess clinical performance, and commercialize a cannabinoid containing transdermal formulation designed and optimized to address both acute and chronic treatment of Resistant Epilepsy, and certain other neurological disorders.

Scientus will be the supplier of specific cannabinoid extracts and will have an option to co-fund the clinical development of this program. The parties expect to expand the collaboration to additional product development programs in the future.

“We are delighted to collaborate with Scientus for development

... read more at: http://markets.businessinsider.com/news/stocks/Aequus-and-Scientus-Agree-to-Terms-for-a-Medical-Cannabis-Commercial-Supply-and-Product-Development-Collaboration-1002222641

by

Leave a Reply

Your email address will not be published. Required fields are marked *